4 years ago

Baseimmune Raises £3.5 Million to Develop Future-Proof Universal Vaccines

  • Baseimmune, a London-based biotech startup, has secured £3.5 million in funding to develop universal vaccines against existing and emerging threats like COVID, malaria, and African Swine Fever

  • The funding round was led by Hoxton Ventures with participation from Creator Fund, Cherry Ventures, Beast Ventures, Rockmount, and Maki.vc

  • Baseimmune's vaccine design algorithm uses AI to create synthetic antigens that are effective against all current and likely variants of pathogens

  • The company has partnered with DNA vaccine pioneers Touchlight to develop a universal coronavirus vaccine.

      • ProblemHealthcare

      "Current vaccines are often limited in their effectiveness and ability to cope with new variants, as they are based on a single pathogen component. This makes them vulnerable to emerging threats like new strains of viruses."

      Solution

      "Baseimmune's vaccine design algorithm uses AI to analyze genomic, epidemiological, immunological, clinical, and evolutionary data to create synthetic antigens that contain all the parts of a pathogen most likely to trigger a strong immune response. These antigens can be used with any vaccine technology platform, creating universal vaccines that are effective against current and future variants."

      Covered on